Bill > S07807

This bill expands the definition of epinephrine devices to include nasal spray and other FDA-approved delivery methods beyond traditional auto-injectors, while updating various sections of public health, education, and insurance laws to reflect this broader definition. The legislation aims to provide more flexibility in how epinephrine can be administered during medical emergencies, particularly for people experiencing anaphylactic symptoms. Key changes include allowing schools, public places of assembly, and insurance providers to recognize and use a wider range of epinephrine delivery methods. The bill modifies existing laws to replace references to "auto-injectors" with the more inclusive term "epinephrine devices," ensuring that nasal sprays and other FDA-approved methods are treated equivalently to traditional injectable devices. Additionally, the bill maintains existing protections for entities and individuals who use these devices in emergency situations, such as liability limitations and training requirements, while expanding the types of devices that can be used to treat severe allergic reactions.

Health and Social Services

https://www.nysenate.gov/legislation/bills/2025/S7807